• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Bellerophon completes enrollment for phase II trial of INOpulse for PAH

Bellerophon completes enrollment for phase II trial of INOpulse for PAH

June 19, 2014
CenterWatch Staff

Bellerophon Therapeutics, a clinical stage biotherapeutics company has completed enrollment of its 80-patient phase II clinical trial of INOpulse for the treatment of pulmonary arterial hypertension (PAH). PAH is a life-threatening, progressive disorder characterized by abnormal constriction of the arteries of the lung, leading to increased blood pressure in the lungs and abnormal strain on the heart's right ventricle, eventually leading to heart failure.

Bellerophon's INOpulse device delivers brief, controlled pulses of nitric oxide, which is a selective, short-acting pulmonary vasodilator, that are inhaled by the patient. INOpulse is portable, allowing for treatment of ambulatory patients on daily basis outside the hospital.

This phase II study, being conducted at 52 sites in the U.S. and Canada, is a randomized, placebo-controlled trial of INOpulse as an add-on therapy for use in patients whose disease is progressing despite treatment with other PAH medications. The trial will determine the safety, tolerability and efficacy in this population of two different doses of INOpulse for PAH. The primary endpoint is a change in pulmonary vascular resistance at 16 weeks from baseline. Secondary endpoints include change in mean pulmonary arterial pressure and cardiac index as well as change in six-minute walk distance. The trial is expected to be completed by the end of 2014.

"The FDA has granted orphan drug designation for nitric oxide for the treatment of PAH, which will give us seven years of exclusivity in the U.S. if INOpulse is the first inhaled nitric oxide therapy approved in this indication," said Daniel Tasse, interim chief executive officer of Bellerophon. "There is presently no cure for PAH and, despite several approved therapies, the mortality rate remains high. The completion of enrollment in this important phase II trial is therefore a key milestone for Bellerophon, and we look forward to the continued development of this potential new first-in-class therapy."

Prior to the availability of current treatments, primary PAH patients had an average survival of less than three years. There are a number of drugs approved for the treatment of PAH that work by reducing vascular resistance. However, despite the availability of multiple therapies for this indication, the mortality rate for PAH patients remains high, with estimates of median survival ranging from three to five years.

Patients with PAH also report severe impairment of health-related quality of life, including poor general and emotional health and impaired physical functioning. The most common symptoms of PAH are shortness of breath during exertion and fainting spells. Additional symptoms can include dizziness, swelling of the ankles or legs, chest pain and a racing pulse. PAH is classified as an orphan disease by the FDA, indicating that there are fewer than 200,000 patients who have been diagnosed with the condition in the U.S.

Upcoming Events

  • 24May

    Powering an Effective Oversight Strategy with Clinical and Operational Insights

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing